Keytolead gets Vinnova funding

Alligator Bioscience is sharpening its primary focus on its lead asset mitazalimab, and, given current capital restraints, plans to adjust the size of its organization and scope of operations to reflect that.

During the World AMR Awareness Week (WAAW) NLS has chosen to highlight different Nordic companies and investors sharing what part of the solution they bring to the table and how their impact can be leveraged globally. 

Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for Xbrane´s Nivolumab Biosimilar candidate (referencing Opdivo).

The Board of Directors of SciBase has decided to carry out a capital raise totaling approximately SEK 81.8 million.

The company has announced a capital investment in the United States focused on expanding its research and manufacturing footprint by the end of 2026.

Through this investment of 12,500 square meters distributed on four levels, the conditions for continued expansion in the coming years are strengthened.


Abera Bioscience has been awarded a grant from Vinnova to advance the development of its pneumococcal vaccine, Ab-01.12, towards clinical trials.